Navigation Links
Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Date:8/19/2007

Multi-Center International Study to Determine the Efficacy of LBH589 in

Patients with Relapsed or Refractory Multiple Myeloma

NORWALK, Conn., Aug. 14 /PRNewswire-USNewswire/ -- The Multiple Myeloma Research Consortium (MMRC) today announced its participation in a Phase II study to determine the efficacy of LBH589 for the treatment of patients with relapsed or refractory multiple myeloma. LBH589 is an orally administered deacetylase inhibitor developed by Novartis Pharmaceuticals.

The MMRC is the only research model of its kind bringing together 13 leading academic institutions to accelerate the development of novel and combination treatments for multiple myeloma, an incurable cancer of the plasma cell. In addition to its most recent partnership with Novartis, the MMRC is facilitating several other clinical trials, including a Phase I study of NPI- 0052, a proteasome inhibitor, in collaboration with Nereus Pharmaceuticals, and a Phase I study of perifosine, lenalidomide (REVLIMID(R)), and dexamethasone in collaboration with Keryx Biopharmaceuticals.

"Deacetylase inhibitors may represent a new treatment options for cancer patients and the MMRC is proud to work with Novartis to advance this important clinical program," said Kathy Giusti, Founder and Chief Executive Officer of the MMRC, as well as a myeloma patient. "This trial and the others the MMRC is facilitating demonstrate the importance of novel collaborations in bringing new treatments to patients."

Named ALPHA-MM, this trial is a single arm, open label, multi-center global study that will enroll 144 patients in the United States, Canada, and Europe. MMRC Member Institutions that will enroll patients are Dana-Farber Cancer Institute, City of Hope National Medical Center, Emory University, Hackensack University Medical Center, Mayo Clinic, H. Lee Moffitt Cancer Center & Research Institute, and Washington University.

This trial is open to patients with relapsed or refractory multiple myeloma who have received at least two lines of therapy, and whose disease progressed on their most recent therapy. Prior therapy must have included bortezomib (VELCADE(R)) or lenalidomide.

LBH589 is part of a promising class of drugs called deacetylase inhibitors or HDAC inhibitors, which may play an important role in helping to slow or stop the growth of multiple myeloma cells. Preclinical laboratory data suggests that LBH589 has significant activity against multiple myeloma cells, including those that are resistant to conventional therapies.

About the Multiple Myeloma Research Consortium (MMRC)

The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 13 member institutions: City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the Cancer Center at Hackensack University Medical Center, H. Lee Moffitt Cancer Center & Research Institute, Mayo Clinic, Ohio State University, Roswell Park Cancer Institute, St. Vincent's Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York, University Health Network (Princess Margaret Hospital), University of Chicago, University of Michigan, and Washington University.

The MMRC was founded in 2004 by Kathy Giusti, a myeloma patient, and with the help of the scientific community. The MMRC is a sister organization to the Multiple Myeloma Research Foundation (MMRF), the world's leading funder of multiple myeloma research. The MMRC is widely recognized as an optimal research model to rapidly address critical challenges in drug development and to explore opportunities in the today's most promising research areas -- genomics, compound validation, and clinical trials. The MMRC is the only consortium to join academic institutions through membership agreements, customized IT systems, and an integrated tissue bank. For more information, please visit http://www.themmrc.org.


'/>"/>
SOURCE The Multiple Myeloma Research Consortium

Copyright©2007 PR Newswire.

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017 Nevro Corp. (NYSE: NVRO), a global medical ... treatment of chronic pain, today reported financial results for the ... 2016 Accomplishment & Highlights: Achieved ... increase of 228% as reported, over the prior year ... of 612% over the prior year International ...
(Date:2/23/2017)... Research and Markets has announced the addition ... report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and ... global Fibromyalgia market. The research answers the following questions: ... Fibromyalgia and their clinical attributes? How are they positioned in the ...
(Date:2/23/2017)... February 23, 2017 According to ... Product (X-ray Imaging Digital, Analog), MRI (Closed, Open), Ultrasound, ... Cardiology, Oncology), End User (Hospitals, Imaging Centers) - Global ... the global market over the forecast period of 2016 ... 36.43 Billion by 2021, at a CAGR of 6.6% ...
Breaking Medicine Technology:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Top cosmetic ... Smiling Patriot program today with a new Indiegogo campaign . Individuals are ... homeless veterans in the Los Angeles area, either as a participating patient or through ...
(Date:2/23/2017)... ... ... Thomas Vas-Don suffered from severe injury due to an ... successfully recover. In “ Origin & Insertion Charts for Massage Therapists ” (published by ... massage, anatomy , trigger points and referral pain patterns . , In ...
(Date:2/22/2017)... ... 22, 2017 , ... Our high-octane society demands higher stands ... brain. , Power On, a mental performance enhancer from Modus Nutrition, provides scientifically ... capsule contains Cognizin® Citicoline, a branded form of the brain health nutrient citicoline ...
(Date:2/22/2017)... ... , ... The Waismann Method® is providing a faster, safer, and ... victim to America’s opioid epidemic. Now, opiate dependent individuals can be treated in a ... the shame, stigma, and harmful labeling believed to prevent many of these ...
(Date:2/22/2017)... ... , ... South Bend’s Lunkerville, the award-winning TV series that catches real people ... (HOW), a non-profit organization dedicated to helping military veterans relax, rehabilitate, and reintegrate through ... to Lake Denmark, New Jersey, to fish with war veteran Justin Vail from the ...
Breaking Medicine News(10 mins):